Page last updated: 2024-12-05

dulcin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dulcin, also known as 4-ethoxyphenylurea, is a synthetic sweetening agent that was once widely used in food and beverages. It was discovered in 1884 by German chemist Johannes von Liebig. Dulcin is about 250 times sweeter than sucrose (table sugar), and its sweetness is not affected by temperature changes. It was synthesized from para-phenetidine and potassium cyanate. Dulcin was used as a sweetener in many products, but its use declined in the 1950s after it was found to be carcinogenic in laboratory animals. Although Dulcin is no longer used as a sweetener, it is still studied for its potential as a drug. For example, researchers have found that dulcin can protect against liver damage in mice. The research focuses on its potential in drug development and understanding its biological activity.'

dulcin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9013
CHEMBL ID1330343
CHEBI ID82462
SCHEMBL ID177957
MeSH IDM0045381

Synonyms (85)

Synonym
(4-ethoxyphenyl)-urea
dulcin
p-ethoxyphenylurea
p-phenetolcarbamide
valzin
nci-c02073
urea, (p-ethoxyphenyl)-
p-phenetylurea
wln: zvmr do2
p-phenetolcarbamid
150-69-6
dulcine
nsc-1839
phenethylcarbamid
sucrol
nsc1839
p-phenetolecarbamide
dulein
urea, (4-ethoxyphenyl)-
phenetolcarbamide
4-ethoxyphenylurea
p-phenethylurea
suesstoff
p-aethoxyphenylharnstoff
DIVK1C_001135
1-(4-ethoxyphenyl)urea
4-ethoxy-phenylurea
smr000065473
MLS000056892
CDS1_000095
nsc 1839
ccris 5913
phenethylcarbamid [german]
p-ethoxyfenylmocovina [czech]
p-aethoxyphenylharnstoff [german]
p-phenetolcarbamid [german]
brn 2096445
einecs 205-767-7
n-(4-ethoxyphenyl)urea
ai3-08931
MAYBRIDGE1_002383
OPREA1_621725
STK400289
AKOS000113528
HMS548E07
(4-ethoxyphenyl)urea
A809064
BBL004546
HMS2487K12
4-13-00-01154 (beilstein handbook reference)
hsdb 8048
p-ethoxyfenylmocovina
8u78kf577z ,
unii-8u78kf577z
C19415
dtxsid9020580 ,
NCGC00255360-01
dtxcid10580
tox21_301340
cas-150-69-6
FT-0618389
dulcin [iarc]
dulcin [mi]
4-ethoxyphenyl)urea
(p-ethoxyphenyl)urea
4-ureidophenetole
urea,(4-ethoxyphenyl)-
SCHEMBL177957
CHEBI:82462 ,
PS-4228
mfcd00025431
CHEMBL1330343
W-205707
GGLIEWRLXDLBBF-UHFFFAOYSA-N
Z56754688
urea, (4-ethoxyphenyl)- (9ci)
p-ureidophenetole
dulcin?
CS-0206739
E1171
Q423302
AMY202100030
T71814
4-ethoxyphenyl urea
urea, n-(4-ethoxyphenyl)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.98110.044717.8581100.0000AID485294
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen nuclear receptor alphaHomo sapiens (human)Potency68.58960.000229.305416,493.5996AID743079
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.58960.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency51.43500.037617.082361.1927AID1259388
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (42.31)18.7374
1990's2 (7.69)18.2507
2000's6 (23.08)29.6817
2010's6 (23.08)24.3611
2020's1 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.77 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index83.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]